Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Trajectories of Childhood Adversity and Type 1 Diabetes: A Nationwide Study of One Million Children

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Antidiabetes Agents and Incident Depression: A Nationwide Population-Based Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Data Sharing Under the General Data Protection Regulation: Time to Harmonize Law and Research Ethics?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Effect of Dapagliflozin on Clinical Outcomes in Patients with Chronic Kidney Disease, With and Without Cardiovascular Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • LEADER Trial Investigators
Vis graf over relationer

OBJECTIVE: A post hoc analysis to investigate the association between 1-year changes in albuminuria and subsequent risk of cardiovascular and renal events.

RESEARCH DESIGN AND METHODS: LEADER was a randomized trial of liraglutide up to 1.8 mg/day versus placebo added to standard care for 3.5-5 years in 9,340 participants with type 2 diabetes and high cardiovascular risk. We calculated change in urinary albumin-to-creatinine ratio (UACR) from baseline to 1 year in participants with >30% reduction (n = 2,928), 30-0% reduction (n = 1,218), or any increase in UACR (n = 4,124), irrespective of treatment. Using Cox regression, risks of major adverse cardiovascular events (MACE) and a composite nephropathy outcome (from 1 year to end of trial in subgroups by baseline UACR [<30 mg/g, 30-300 mg/g, or ≥300 mg/g]) were assessed. The analysis was adjusted for treatment allocation alone as a fixed factor and for baseline variables associated with cardiovascular and renal outcomes.

RESULTS: For MACE, hazard ratios (HRs) for those with >30% and 30-0% UACR reduction were 0.82 (95% CI 0.71, 0.94; P = 0.006) and 0.99 (0.82, 1.19; P = 0.912), respectively, compared with any increase in UACR (reference). For the composite nephropathy outcome, respective HRs were 0.67 (0.49, 0.93; P = 0.02) and 0.97 (0.66, 1.43; P = 0.881). Results were independent of baseline UACR and consistent in both treatment groups. After adjustment, HRs were significant and consistent in >30% reduction subgroups with baseline micro- or macroalbuminuria.

CONCLUSIONS: A reduction in albuminuria during the 1st year was associated with fewer cardiovascular and renal outcomes, independent of treatment. Albuminuria monitoring remains an important part of diabetes care, with great unused potential.

OriginalsprogEngelsk
TidsskriftDiabetes Care
Vol/bind44
Udgave nummer4
Sider (fra-til)1020-1026
Antal sider7
ISSN1935-5548
DOI
StatusUdgivet - apr. 2021

ID: 61965103